Since 2017, Aplagon has a clinical development and commercialization agreement with India’s Cadila Pharmaceucials, for commercialization of APAC in India to prevent blood vessel occlusions related to vascular interventions.
APAC has a wide range of applications in severe cardiovascular diseases, based on its broad mode of action.
We welcome enquires about partnering opportunities to co-develop and commercialise APAC.
email: aki.prihti@aplagon.com
